DDInter1821 DDInter927
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Tizanidine {u} (Compound) resembles {v} (Compound) Brimonidine
Tizanidine {u} (Compound) binds {v} (Gene) CYP1A2
Tizanidine {u} (Compound) upregulates {v} (Gene) CDK6
Tizanidine {u} (Compound) palliates {v} (Disease) multiple sclerosis
Tizanidine {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Tizanidine {u} (Compound) downregulates {v} (Gene) USP22
Tizanidine {u} (Compound) causes {v} (Side Effect) Autonomic nervous system imbalance
Tizanidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Tizanidine (Compound) resembles Brimonidine (Compound)
Tizanidine (Compound) binds CYP1A2 (Gene)
Tizanidine (Compound) upregulates CDK6 (Gene)
Tizanidine (Compound) palliates multiple sclerosis (Disease)
Tizanidine (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Tizanidine (Compound) downregulates USP22 (Gene)
Tizanidine (Compound) causes Autonomic nervous system imbalance (Side Effect)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a